HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies.
HER2
HER3
breast cancer
drug resistance
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380
Informations de publication
Date de publication:
08 05 2020
08 05 2020
Historique:
received:
24
09
2019
revised:
24
03
2020
accepted:
29
03
2020
pubmed:
25
4
2020
medline:
19
8
2021
entrez:
25
4
2020
Statut:
ppublish
Résumé
Despite impressive clinical benefit obtained with anti-HER2-targeted therapies, in advances stages, especially in the metastatic setting, HER2-positive tumors remain incurable. Therefore, it is important to develop novel strategies to fight these tumors, especially when they become resistant to available therapies. We show here that the anti-HER3 antibody-drug conjugate EV20/MMAF exerted potent anti-tumoral properties against several models of primary resistance and secondary resistance to common anti-HER2 available therapies, including trastuzumab, lapatinib, neratinib, and trastuzumab-emtansine. HER3 was expressed in these HER2
Identifiants
pubmed: 32329582
doi: 10.15252/emmm.201911498
pmc: PMC7207167
doi:
Substances chimiques
Antineoplastic Agents
0
Immunoconjugates
0
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e11498Subventions
Organisme : Ministerio de Economía y Competitividad (MEC)
ID : BFU2015-71371-R
Pays : International
Organisme : Ministerio de Economía y Competitividad (MEC)
ID : BES-2016-077748
Pays : International
Organisme : MEC|Instituto de Salud Carlos III (ISCIII)
ID : RD12/0036/0003
Pays : International
Organisme : Centro de Investigación Biomédica en Red-Cáncer
ID : ONCG40
Pays : International
Organisme : Fundación Científica Asociación Española Contra el Cáncer (AECC)
Pays : International
Organisme : Fundación Cris Contra El Cáncer
Pays : International
Organisme : European Community through the Regional Development Funding Program (FEDER)
Pays : International
Organisme : Associazione Italiana per la Ricerca sul Cancro (AIRC)
ID : IG GRANT 2016, Id 18467
Pays : International
Organisme : ALMOM
Pays : International
Informations de copyright
© 2020 The Authors. Published under the terms of the CC BY 4.0 license.
Références
Nat Med. 2000 Apr;6(4):443-6
pubmed: 10742152
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
N Engl J Med. 2006 Dec 28;355(26):2733-43
pubmed: 17192538
Oncol Rev. 2018 May 16;12(1):355
pubmed: 30057690
Oncotarget. 2015 Oct 6;6(30):30057-71
pubmed: 26336133
Clin Breast Cancer. 2011 Oct;11(5):275-82
pubmed: 21729661
EMBO Mol Med. 2020 May 8;12(5):e11498
pubmed: 32329582
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Transl Oncol. 2013 Dec 01;6(6):676-84
pubmed: 24466370
Hum Vaccin Immunother. 2016 Mar 3;12(3):576-92
pubmed: 26529100
Oncogene. 2020 Jan;39(3):487-502
pubmed: 31519989
Science. 1987 Jul 10;237(4811):178-82
pubmed: 2885917
Oncogene. 2012 Mar 8;31(10):1275-86
pubmed: 21822299
J Control Release. 2018 May 10;277:48-56
pubmed: 29550398
J Natl Cancer Inst. 2010 Sep 22;102(18):1432-46
pubmed: 20811002
Lancet Oncol. 2016 Mar;17(3):367-377
pubmed: 26874901
Trends Cancer. 2020 Feb;6(2):130-146
pubmed: 32061303
Curr Pharm Des. 2016;22(39):5887-5898
pubmed: 27426127
Oncogene. 2016 May;35(21):2756-65
pubmed: 26364598
Cancer Treat Rev. 2018 Jul;68:111-123
pubmed: 29944978
Clin Cancer Res. 2013 Feb 1;19(3):610-9
pubmed: 23224399
Oncotarget. 2018 Aug 7;9(61):31915-31919
pubmed: 30159132
J Clin Oncol. 2015 Apr 20;33(12):1334-9
pubmed: 25559818
Cancer Res. 2002 Jun 1;62(11):3151-8
pubmed: 12036928
Cytometry A. 2010 Apr;77(4):387-98
pubmed: 20151455
Oncotarget. 2017 Sep 8;8(56):95412-95424
pubmed: 29221137
Ther Adv Med Oncol. 2019 Mar 19;11:1758835919833519
pubmed: 30911337
Oncogene. 2019 Feb;38(9):1398-1409
pubmed: 30302022
Oncotarget. 2015 Jul 10;6(19):16902-11
pubmed: 26160848
Clin Cancer Res. 2007 Aug 15;13(16):4909-19
pubmed: 17699871
Mol Cancer Ther. 2019 Nov;18(11):2043-2050
pubmed: 31395690
J Natl Cancer Inst. 2014 Sep 24;106(11):
pubmed: 25253614
Int J Cancer. 2019 Oct 1;145(7):1838-1851
pubmed: 30882895
Ann Oncol. 2008 Nov;19(11):1860-9
pubmed: 18641009
Cancer Res. 2017 Sep 1;77(17):4639-4651
pubmed: 28687619
Nat Rev Cancer. 2009 Jul;9(7):463-75
pubmed: 19536107
Cancer Res. 2018 May 1;78(9):2159-2165
pubmed: 29653942
Clin Cancer Res. 2019 Dec 1;25(23):7151-7161
pubmed: 31471314
J Cell Biol. 1996 Feb;132(3):427-36
pubmed: 8636219
Mol Cell Biol. 2000 May;20(9):3210-23
pubmed: 10757805
Mol Cancer. 2014 May 08;13:105
pubmed: 24886126
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059433
Cancer Res. 2008 Mar 1;68(5):1471-7
pubmed: 18316611
Clin Cancer Res. 2014 Jan 15;20(2):456-68
pubmed: 24097864
Cancer Lett. 2019 Jul 1;453:34-44
pubmed: 30928382
Cancer Res. 2009 Mar 15;69(6):2191-4
pubmed: 19276389
Cancer Cell. 2002 Aug;2(2):127-37
pubmed: 12204533
Nat Rev Cancer. 2009 Jan;9(1):28-39
pubmed: 19104514
J Clin Invest. 2013 May;123(5):2155-68
pubmed: 23543055
J Immunol Methods. 2016 Apr;431:11-21
pubmed: 26851520
Cancer Lett. 2020 Feb 1;470:161-169
pubmed: 31765734
Biol Proced Online. 2019 Mar 19;21:5
pubmed: 30930695
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5021-6
pubmed: 21385943
Nature. 2007 Jan 25;445(7126):437-41
pubmed: 17206155
Am J Physiol. 1994 Jul;267(1 Pt 1):C166-76
pubmed: 8048477
Cancer Cell. 2006 Dec;10(6):515-27
pubmed: 17157791
Aging (Albany NY). 2015 Nov;7(11):899-900
pubmed: 26590357
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2718-23
pubmed: 21368164
Am J Pathol. 2019 Oct;189(10):1898-1912
pubmed: 31351986
J Clin Invest. 2020 Jan 2;130(1):374-388
pubmed: 31661465
Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32
pubmed: 22124364
Annu Rev Pharmacol Toxicol. 2004;44:195-217
pubmed: 14744244
Int J Cancer. 2012 Jul 1;131(1):244-52
pubmed: 21826647